Xeris Biopharma Holdings, Inc.

Annual Trend FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Net income (loss) ($91.1m) ($122.7m) ($94.7m) ($62.3m) ($54.8m) $554k
Depreciation $1.5m $1.3m $1.4m $1.5m $1.2m $1.3m
Amortization of intangible assets $0 $550k $10.8m $10.8m $10.8m $10.8m
Amortization of premium/discount on investments ($84k) ($413k) ($184k) ($1.3m) ($747k) $0
Amortization of debt discount and debt issuance costs $980k $961k $1.6m $2.2m $3.0m $3.4m
Amortization of operating right-of-use assets $0 $426k $830k $555k $537k
Deferred income tax expense (benefit) $0 ($1.4m) ($1.2m) ($2.3m) $0
Loss on debt extinguishment, net ($443k) $0 ($1.2m) $2.8m $0 $0
Operating lease liabilities $0 ($899k) $7.5m $1.1m ($1.6m)
Stock-based compensation $8.3m $11.4m $12.2m $10.7m $18.4m $22.4m
Change in fair value of contingent value rights $0 $3.2m ($5.2m) ($4.4m) $0
Other $3.2m ($1.4m) $2.5m $3.4m ($1.1m) $3.7m
Trade accounts receivable $2.2m $6.2m $13.4m ($8.4m) ($1.2m) ($10.6m)
Prepaid expenses and other current assets ($925k) ($3.3m) $3.9m $3.2m ($1.7m) ($2.1m)
Inventory $5.1m $7.4m $7.5m ($14.8m) ($8.8m) ($19.3m)
Accounts payable ($2.5m) $5.5m ($4.3m) $7.0m ($9.6m) ($69k)
Other accrued liabilities ($2.2m) $12.6m ($11.4m) ($5.9m) $3.6m $3.3m
Accrued trade discounts and rebates $4.6m $4.2m $1.8m $5.3m $3.9m $16.4m
Accrued returns reserve $932k $1.1m $7.2m $3.0m $4.9m ($113k)
Increase (Decrease) In Supply Agreement Liabilities $0 ($5.3m) ($6.7m) $0 $0
Proceeds from issuance of employee stock purchase plan shares $669k $642k $828k $549k $1.2m $1.5m
Proceeds from exercise of stock options $135k $193k $8k $32k $489k $11.6m
Proceeds from Issuance of Warrants $0 $0 $9.2m
Issuance of common shares in settlement of CVR liability $0 $0 $15.8m $0
Issuance of convertible note $0 $0 $33.6m $0 $0
Restricted cash included in Other assets (1) $0 $4.3m $4.2m $4.1m $4.0m
Net cash provided by (used in) operating activities ($80.6m) ($95.5m) ($102.9m) ($47.0m) ($37.0m) $28.6m
Capital expenditures $377k $1.1m ($524k) ($2.3m) ($868k) ($696k)
Purchases of investments ($101.8m) ($43.0m) $0 ($43.7m) ($34.5m) $0
Sales and maturities of investments $74.7m $103.6m $35.0m $40.0m $40.2m $0
Net cash provided by (used in) investing activities ($27.4m) $98.0m $34.5m ($6.0m) $4.9m ($696k)
Proceeds from debt refinancing $0 $0 $50.0m $0
Payments of debt issuance costs $5.6m $0 $4.9m ($1.2m) $0 $0
Issuance of common shares in partial settlement of 2025 Convertible Debt $0 $0 $15.1m
Payment of debt discount $0 $0 ($11.8m) $0
Repurchase of common stock withheld for taxes $63k $534k $468k ($1.0m) ($3.7m) ($10.9m)
Net cash provided by (used in) financing activities $126.1m $27.2m $127.5m ($1.6m) $36.2m $11.4m
Net cash provided by (used in) in cash, cash equivalents and restricted cash $29.7m $59.0m ($54.6m) $4.1m $39.3m
Cash, cash equivalents and restricted cash, beginning of year $67.3m $126.3m $71.7m $75.7m $115.1m
Cash and cash equivalents $37.6m $67.3m $122.0m $67.4m $71.6m $111.0m
Cash paid for interest $4.6m $7.3m $10.9m $27.7m $26.9m $27.1m